Overview

Analysis of Body Mass Index in Central Precocious Puberty Patients Treated With Leuprolide Acetate

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
Analysis of body mass index in Central Precocious Puberty patients treated with leuprolide acetate
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Kyungpook National University
Kyungpook National University Hospital
Treatments:
Leuprolide
Criteria
Inclusion Criteria:

1. Child diagnosed with CPP who has a peak-stimulated Lutenizing Hormone(LH)
concentration over 5 IU/liter before initiation of therapy

2. Chronological age(CA) at the appearance of pubertal changes less than 8 years in girls
and less than 9 years in boys.

3. Tanner stage ≥2

4. Advanced bone age (Bone Age/Chronological Age >1.1)

5. Able to have the signed written informed consent provided by the patients' parents or
legal guardians prior to any study-related procedures

Exclusion Criteria:

1. Patient with a peripheral precocious puberty: extrapituitary secretion of
gonadotropins or gonadotropin-independent gonadal or adrenal sex steroids secretion

2. Patient with a cerebral tumor requiring a neurosurgery or cerebral irradiation known
chronic disease of underlying medical condition

3. Currently on or planning growth hormone treatment

4. Previous Gonadotropin-Releasing Hormone agonist treatment

5. Any patient who in opinion of the investigator should not participate in the study